Search

test

...

Editing with Contributor

pece_annotation_1472844848

tamar.rogoszinski
Annotation of
In response to

The article is published in the Japanese Journal of Clinical Oncology. It is meant for clinical oncologists and publishes articles on medical oncology, clinical trials, radiology, surgery, basic research, epidemiology, and palliative care. It was established in 1971 and is the first journal from Japan to publish clinical research on cancer in English. Since 1977, JJCO is a sister-journal to the Journal of the National Cancer Institute and is linked through Oxford Journals. 

pece_annotation_1479073541

tamar.rogoszinski
Annotation of
In response to

This PDF does not include the bibliography, but it is clear that a lot of the work is original due to his traveling and conducting of research. His citatiosn throughout the chapter indicate that he did reference other knowledgable and notable anthropologists and their work helped frame his argument. 

pece_annotation_1473449061

tamar.rogoszinski
Annotation of
In response to
    1. “…large­-scale social forces—racism, gender inequality, poverty, political violence and war, and sometimes the very policies that address them—often determine who falls ill and who has access to care.”
    2. "the holy grail of modern medicine remains the search for the molecular basis of disease."
    3. "In some senses, the model is simple: clinical and community barriers to care are removed as diagnosis and treatment are declared a public good and made available free of charge to patients living in poverty."
    4. "The poor are the natural constituents of public health, and physicians ... are the natural attourneys of the poor."

     

     

    pece_annotation_1473995548

    tamar.rogoszinski
    Annotation of
    In response to
    1. I first looked up travel to and from Liberia during the Ebola outbreak, since it had been seized. There was a ban, which has since been lifted after, but people coming to and from West Africa are still screened and recommended to visit physicians. As of mid-2015 there wa still a 21 day monitoring period needed. http://www.infectioncontroltoday.com/news/2015/05/cdc-downgrades-travel…'
    2. I was interested if there had been any progress on treatment for Ebola, but found that the main form of treatment is supportive care. Doctors are informed to provide IV fluid and ensure that the patient's immune response and other bodily functions are functioning properly. A vaccine is being worked on but has not gone through a trial to prove safety and effectiveness. https://www.cdc.gov/vhf/ebola/treatment/index.html
    3. I looked further into the vaccine being produced for Ebola. Currently, there is a combined phase 2 and phase 3 trial occurring in Sierra Leone called STRIVE (Sierra Leone Trial to Introduce a Vaccine against Ebola). The study is unblinded, so patients know whether or not they have received the vaccine. The vaccine is a rVSV-ZEBOV, or recombinant Vesicular Stomatitis Virus Zaire ebolavirus vaccine. This vaccine is also being used in phase 2 and phase 3 trials in Guinea and Liberia http://www.cdc.gov/vhf/ebola/strive/qa.html